These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 27029727)

  • 101. Galectin-3: a possible complementary marker to the PSA blood test.
    Balan V; Wang Y; Nangia-Makker P; Kho D; Bajaj M; Smith D; Heilbrun L; Raz A; Heath E
    Oncotarget; 2013 Apr; 4(4):542-9. PubMed ID: 23625538
    [TBL] [Abstract][Full Text] [Related]  

  • 102. [Early detection or screening in the prevention of prostate cancer?].
    Brenes Bermúdez FJ; Alcántara Montero A
    Semergen; 2017 Mar; 43(2):100-108. PubMed ID: 26960257
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Prostate-specific antigen as a tumor marker in prostate cancer.
    Kuriyama M
    Int J Urol; 1994 Jun; 1(2):99-113. PubMed ID: 7543013
    [No Abstract]   [Full Text] [Related]  

  • 104. Response.
    Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2015 Jun; 107(6):djv111. PubMed ID: 25888717
    [No Abstract]   [Full Text] [Related]  

  • 105. Re: histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish Prostate Cancer Screening Trial.
    Schaeffer EM
    J Urol; 2014 Jun; 191(6):1808. PubMed ID: 25280286
    [No Abstract]   [Full Text] [Related]  

  • 106. Prostate-specific antigen and premalignant change: implications for early detection.
    Brawer MK; Lange PH
    CA Cancer J Clin; 1989; 39(6):361-75. PubMed ID: 2482117
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Prostate cancer prevention: do the 5-ARIs make the grade?
    Parnes HL
    Am J Bioeth; 2011 Dec; 11(12):30-1. PubMed ID: 22146028
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Prostatic fluid electrolyte composition for the screening of prostate cancer: a potential solution to a major problem.
    Costello LC; Franklin RB
    Prostate Cancer Prostatic Dis; 2009; 12(1):17-24. PubMed ID: 18591961
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Evolving detection and treatment methods change approaches to prostate cancer: US Preventive Services Task Force draft recommendations now align more closely with others.
    Printz C
    Cancer; 2018 Jan; 124(1):11-12. PubMed ID: 29251768
    [No Abstract]   [Full Text] [Related]  

  • 110. Patented prostate cancer biomarkers.
    Murphy L; Watson RW
    Nat Rev Urol; 2012 Aug; 9(8):464-72. PubMed ID: 22750955
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Screening for prostate cancer.
    Wilson SS; Crawford ED
    Clin Prostate Cancer; 2004 Jun; 3(1):21-5. PubMed ID: 15279686
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Risk-based prostate cancer screening: who and how?
    Glass AS; Cary KC; Cooperberg MR
    Curr Urol Rep; 2013 Jun; 14(3):192-8. PubMed ID: 23532499
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Recent progress and perspectives on prostate cancer biomarkers.
    Hatakeyama S; Yoneyama T; Tobisawa Y; Ohyama C
    Int J Clin Oncol; 2017 Apr; 22(2):214-221. PubMed ID: 27730440
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Prostate-specific antigen or human kallikrein 3? Recent developments.
    Diamandis EP
    Tumour Biol; 1998; 19(2):65-7; discussion 67-8. PubMed ID: 9486557
    [No Abstract]   [Full Text] [Related]  

  • 115. An Experimental Platform for Characterizing Cancer Biomarkers with Capabilities in Noninvasive and Continuous Screening.
    Honikel MM; La Belle JT
    Crit Rev Biomed Eng; 2019; 47(3):217-234. PubMed ID: 31679257
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Biomarkers for prostate cancer detection and progression: Beyond prostate-specific antigen.
    Berney DM
    Drug News Perspect; 2010 Apr; 23(3):185-94. PubMed ID: 20440420
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Prostate-specific antigen, risk factors, and prostate cancer: confounders nestled in an enigma.
    Thompson IM; Ankerst DP; Tangen CM
    J Natl Cancer Inst; 2010 Sep; 102(17):1299-301. PubMed ID: 20724727
    [No Abstract]   [Full Text] [Related]  

  • 118. Number needed to screen--how can we project outside context?
    Auvinen A
    J Clin Epidemiol; 2011 Dec; 64(12):1275-6. PubMed ID: 22032752
    [No Abstract]   [Full Text] [Related]  

  • 119. [Early detection of prostate cancer: a summary of the past 10 years].
    Vaccaro F; Roosendaal A; Iselin C
    Rev Med Suisse; 2020 Dec; 16(717):2330-2333. PubMed ID: 33263957
    [TBL] [Abstract][Full Text] [Related]  

  • 120. [Effects of modified inclusion criteria and negative reporting about PSA screening on the number of potentially recruitable patients for the PREFERE study].
    Mathes J; Burger M; Gschwend JE; Hakenberg OW; Krege S; Lehmann J; Miller K; Roigas J; Roth S; Kälble T
    Urologe A; 2016 Sep; 55(9):1213-7. PubMed ID: 27538967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.